Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 OctoPlus N.V. | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

OctoPlus N.V.

Jan Hendrik Egberts, M.D. has been appointed chief executive officer of

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jan Hendrik Egberts, M.D. has been appointed chief executive officer of OctoPlus N.V. Dr. Egberts replaces Simon Sturge, who will leave the company January 1, 2011 to take a position with a top pharmaceutical company. Dr. Egberts will work with Mr. Sturge until the end of this year to ensure a smooth transition.

Dr. Egberts has more than 20 years of experience in the pharmaceutical industry. He worked for four years as a strategic consultant to life sciences companies at McKinsey & Co., and from 1994 onwards held business development and general management positions of increasing responsibility in the U.S. at Merck, Johnson & Johnson and Mölnlycke Health Care. He also served as chief executive officer of Novadel Pharmaceuticals, Inc. and senior advisor in healthcare investments to private equity firm 3i Group.

“The board of supervisory directors is proud to have recruited Jan Hendrik Egberts as CEO. He is a highly experienced and skilled professional and we look forward to welcoming him to the executive team. We are sorry to see Simon go but we understand his decision to act on a unique job opportunity,” said Hans Stellingsma, chairman of the board of OctoPlus.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters